Risk stratification model for the pharmaceutical care of oncology patients with solid or hematologic neoplasms
CONCLUSION: This stratification model enables the identification of cancer patients requiring a higher level of pharmaceutical care and facilitates the adjustment of care capacity. Validation of the model in a representative population is necessary to establish its effectiveness.PMID:37884399 | DOI:10.1016/j.farma.2023.07.013 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - October 26, 2023 Category: Drugs & Pharmacology Authors: Beatriz Bernardez Irene Mangues-Bafalluy Virginia Mart ínez Callejo Juan Jos é Fernández Ávila Jose Antonio Marcos Rodr íguez Maria Angeles Parada Aradilla Mar ía José Martínez Bautista Source Type: research
[Translated article] Utilization of emicizumab in the treatment of a case of acquired haemophilia A
Farm Hosp. 2023 Oct 24:S1130-6343(23)00898-X. doi: 10.1016/j.farma.2023.10.002. Online ahead of print.NO ABSTRACTPMID:37884400 | DOI:10.1016/j.farma.2023.10.002 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - October 26, 2023 Category: Drugs & Pharmacology Authors: Mar ía Ángeles Ocaña Gómez Jorge Esquivel Negr ín Mario R íos De Paz Mar ía Dolores De Dios García Source Type: research
[Translated article] Checklist for the pharmaceutical care of patients with interstitial lung disease (CheckEPID): A Delphi-based consensus
CONCLUSIONS: The management of patients with ILD and/or pulmonary fibrosis is complex and requires a multidisciplinary approach where the hospital pharmacist plays a key role, especially, although not only, in monitoring drug treatment. We believe that this checklist can contribute from pharmaceutical care to improving the integrated care of patients with ILD who require or are undergoing treatment with antifibrotic drugs.PMID:37865593 | DOI:10.1016/j.farma.2023.09.004 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - October 21, 2023 Category: Drugs & Pharmacology Authors: Marta Calvin-Lamas Miguel Ángel Calleja Hernández Emilio Monte-Boquet Miguel Ángel Rodriguez Sagrado Pere Ventayol Bosch Source Type: research
[Translated article] Checklist for the pharmaceutical care of patients with interstitial lung disease (CheckEPID): A Delphi-based consensus
CONCLUSIONS: The management of patients with ILD and/or pulmonary fibrosis is complex and requires a multidisciplinary approach where the hospital pharmacist plays a key role, especially, although not only, in monitoring drug treatment. We believe that this checklist can contribute from pharmaceutical care to improving the integrated care of patients with ILD who require or are undergoing treatment with antifibrotic drugs.PMID:37865593 | DOI:10.1016/j.farma.2023.09.004 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - October 21, 2023 Category: Drugs & Pharmacology Authors: Marta Calvin-Lamas Miguel Ángel Calleja Hernández Emilio Monte-Boquet Miguel Ángel Rodriguez Sagrado Pere Ventayol Bosch Source Type: research
[Translated article] Checklist for the pharmaceutical care of patients with interstitial lung disease (CheckEPID): A Delphi-based consensus
CONCLUSIONS: The management of patients with ILD and/or pulmonary fibrosis is complex and requires a multidisciplinary approach where the hospital pharmacist plays a key role, especially, although not only, in monitoring drug treatment. We believe that this checklist can contribute from pharmaceutical care to improving the integrated care of patients with ILD who require or are undergoing treatment with antifibrotic drugs.PMID:37865593 | DOI:10.1016/j.farma.2023.09.004 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - October 21, 2023 Category: Drugs & Pharmacology Authors: Marta Calvin-Lamas Miguel Ángel Calleja Hernández Emilio Monte-Boquet Miguel Ángel Rodriguez Sagrado Pere Ventayol Bosch Source Type: research
[Translated article] Checklist for the pharmaceutical care of patients with interstitial lung disease (CheckEPID): A Delphi-based consensus
CONCLUSIONS: The management of patients with ILD and/or pulmonary fibrosis is complex and requires a multidisciplinary approach where the hospital pharmacist plays a key role, especially, although not only, in monitoring drug treatment. We believe that this checklist can contribute from pharmaceutical care to improving the integrated care of patients with ILD who require or are undergoing treatment with antifibrotic drugs.PMID:37865593 | DOI:10.1016/j.farma.2023.09.004 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - October 21, 2023 Category: Drugs & Pharmacology Authors: Marta Calvin-Lamas Miguel Ángel Calleja Hernández Emilio Monte-Boquet Miguel Ángel Rodriguez Sagrado Pere Ventayol Bosch Source Type: research
Characterization and real-live results of nebulized voriconazole: A single-center observational study
CONCLUSION: Voriconazole nebulization is well tolerated and it is not absorbed into the systemic circulation; further research is needed to assess its efficacy.PMID:37858518 | DOI:10.1016/j.farma.2023.09.006 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - October 20, 2023 Category: Drugs & Pharmacology Authors: Maria Larrosa-Garcia S ònia Terradas Campanario Aurora Fern ández Polo Carme Ca ñete Ramírez Alba Pau Parra David Campany Herrero Source Type: research
Antiemetic prophylaxis in hematologic malignancies patients receiving conditioning protocols for hematopoietic stem cell transplantation: A study protocol for a systematic review
This study aims to synthesize available evidence on antiemetic prophylaxis regimens in patients with hematologic malignancies undergoing hematopoietic stem cell transplantation, in order to identify the best standard of care.METHODS: A systematic review will be conducted using MEDLINE via PubMed, EMBASE, ClinicalTrials.gov., and Cochrane databases. Studies written in English, French, Italian or Spanish will be considered. After screening the literature according to the inclusion and exclusion criteria, two independent reviewers will extract data and assess the risk of bias in eligible articles. This protocol has been prepa...
Source: Farmacia Hospitalaria - October 20, 2023 Category: Drugs & Pharmacology Authors: Nerea Ba éz-Gutierrez Paloma Su árez-Casillas Maria Antonia P érez-Moreno Cristina Bl ázquez-Goñi Laila Abdelkader-Mart ín Source Type: research
Characterization and real-live results of nebulized voriconazole: A single-center observational study
CONCLUSION: Voriconazole nebulization is well tolerated and it is not absorbed into the systemic circulation; further research is needed to assess its efficacy.PMID:37858518 | DOI:10.1016/j.farma.2023.09.006 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - October 20, 2023 Category: Drugs & Pharmacology Authors: Maria Larrosa-Garcia S ònia Terradas Campanario Aurora Fern ández Polo Carme Ca ñete Ramírez Alba Pau Parra David Campany Herrero Source Type: research
Antiemetic prophylaxis in hematologic malignancies patients receiving conditioning protocols for hematopoietic stem cell transplantation: A study protocol for a systematic review
This study aims to synthesize available evidence on antiemetic prophylaxis regimens in patients with hematologic malignancies undergoing hematopoietic stem cell transplantation, in order to identify the best standard of care.METHODS: A systematic review will be conducted using MEDLINE via PubMed, EMBASE, ClinicalTrials.gov., and Cochrane databases. Studies written in English, French, Italian or Spanish will be considered. After screening the literature according to the inclusion and exclusion criteria, two independent reviewers will extract data and assess the risk of bias in eligible articles. This protocol has been prepa...
Source: Farmacia Hospitalaria - October 20, 2023 Category: Drugs & Pharmacology Authors: Nerea Ba éz-Gutierrez Paloma Su árez-Casillas Maria Antonia P érez-Moreno Cristina Bl ázquez-Goñi Laila Abdelkader-Mart ín Source Type: research
[Translated article] Oral vancomycin in a pediatric patient with primary sclerosing cholangitis and inflammatory bowel disease
Farm Hosp. 2023 Oct 16:S1130-6343(23)00886-3. doi: 10.1016/j.farma.2023.09.005. Online ahead of print.NO ABSTRACTPMID:37852822 | DOI:10.1016/j.farma.2023.09.005 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - October 18, 2023 Category: Drugs & Pharmacology Authors: Cristo Yared P érez Martin Jos é Ramón Alberto Alonso Jenifer Gonz ález Chávez Mar ía Pilar Díaz Ruiz Marta Su árez González Javier Merino Alonso Source Type: research
[Translated article] Oral vancomycin in a pediatric patient with primary sclerosing cholangitis and inflammatory bowel disease
Farm Hosp. 2023 Oct 16:S1130-6343(23)00886-3. doi: 10.1016/j.farma.2023.09.005. Online ahead of print.NO ABSTRACTPMID:37852822 | DOI:10.1016/j.farma.2023.09.005 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - October 18, 2023 Category: Drugs & Pharmacology Authors: Cristo Yared P érez Martin Jos é Ramón Alberto Alonso Jenifer Gonz ález Chávez Mar ía Pilar Díaz Ruiz Marta Su árez González Javier Merino Alonso Source Type: research
[Translated article] Adjusted indirect comparison of zanubrutinib and ibrutinib in first-line treatment of chronic lymphocytic leukemia
CONCLUSIONS: Assuming the uncertainty associated with the adjusted indirect comparison, zanubrutinib could be considered equivalent in efficacy to ibrutinib, however, the presence of differentiating safety features precludes assigning the 2 alternatives as equivalent therapeutic alternatives.PMID:37845105 | DOI:10.1016/j.farma.2023.09.008 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - October 16, 2023 Category: Drugs & Pharmacology Authors: Francisco Javier Salmer ón-Navas Ester Mar ía Barreiro-Fernández Silvia F énix-Caballero Source Type: research
[Translated article] Adjusted indirect comparison of zanubrutinib and ibrutinib in first-line treatment of chronic lymphocytic leukemia
CONCLUSIONS: Assuming the uncertainty associated with the adjusted indirect comparison, zanubrutinib could be considered equivalent in efficacy to ibrutinib, however, the presence of differentiating safety features precludes assigning the 2 alternatives as equivalent therapeutic alternatives.PMID:37845105 | DOI:10.1016/j.farma.2023.09.008 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - October 16, 2023 Category: Drugs & Pharmacology Authors: Francisco Javier Salmer ón-Navas Ester Mar ía Barreiro-Fernández Silvia F énix-Caballero Source Type: research
[Translated article] Adjusted indirect comparison of zanubrutinib and ibrutinib in first-line treatment of chronic lymphocytic leukemia
CONCLUSIONS: Assuming the uncertainty associated with the adjusted indirect comparison, zanubrutinib could be considered equivalent in efficacy to ibrutinib, however, the presence of differentiating safety features precludes assigning the 2 alternatives as equivalent therapeutic alternatives.PMID:37845105 | DOI:10.1016/j.farma.2023.09.008 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - October 16, 2023 Category: Drugs & Pharmacology Authors: Francisco Javier Salmer ón-Navas Ester Mar ía Barreiro-Fernández Silvia F énix-Caballero Source Type: research
